C2N 8E12

Drug Profile

C2N 8E12

Alternative Names: ABBV-8E12; C2N-8E12

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator C2N Diagnostics
  • Developer AbbVie; C2N Diagnostics
  • Class Antibodies; Antiparkinsonians; Monoclonal antibodies
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Progressive supranuclear palsy

Most Recent Events

  • 19 Dec 2016 Adverse events data from a phase I clinical trial in Progressive supranuclear palsy (In elderly, In adults) released by C2N Diagnostics (NCT02494024)
  • 09 Dec 2016 AbbVie and C2N Diagnostics plans a phase II trial for Alzheimer’s disease and Progressive supranuclear palsy
  • 09 Dec 2016 AbbVie plans a phase II trial for Progressive supranuclear palsy in USA (NCT02985879)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top